FIELD: medicine.
SUBSTANCE: present invention relates to medicine, namely to endocrinology and psychiatry, and concerns treating obesity in patients with severe depressive disorder. For that naltrexone and bupropion are introduced in amount of 32 mg/day and 360 mg/day respectively.
EFFECT: introduction of complex of these preparations provides effective weight reduction in patients with severe depressive disorder, comparable with results obtained in patients not suffering from severe depressive disorder.
22 cl, 1 tbl, 3 ex
Authors
Dates
2017-04-17—Published
2011-01-10—Filed